Loading...
Loading...
- Ocuphire Pharma Inc OCUP announced data from the VEGA-1 Phase 2 trial evaluating the efficacy and safety of Nyxol in combination with low-dose pilocarpine (LDP) in presbyopic subjects.
- Presbyopic is the gradual loss of the eye's ability to focus on nearby objects.
- 61% of subjects treated with Nyxol + LDP improved 15 letters or greater in photopic binocular near vision at 1 hour than 28% of subjects on placebo with statistical significance.
- Met the Phase 3 co-primary endpoint vs. placebo gaining 15 letters near vision with less than five letters of distance vision loss.
- Rapid onset of efficacy at 30 mins.
- Durable near vision improvement through at least 6 hours.
- A sustained significant reduction in pupil diameter over at least 18 hours due to the long-lasting effects of Nyxol.
- No severe adverse events (AEs) were reported. Almost all AEs were mild. No headaches, no brow aches, and no blurry vision AEs were reported.
- Mild, transient conjunctival hyperemia (eye redness) was observed in less than 5% of subjects.
- The company plans to initiate Phase 3 trials for presbyopia in 2022 and a second Nyxol Phase 3 trial for Reversal of Mydriasis later this year.
- Price Action: OCUP shares are up 66.5% at $7.81 during the premarket session on the last check Wednesday.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in